Chronic Toxicity in Wistar Rats of Cytoreg, An Ionic Antineoplastic Therapeutic Mix of Strong and Weak Acids

Drugs are used for prevention, diagnosis and treatment of diseases of humans or other living things. The efficacy and safety of new drugs must be shown in order for the compounds to become marketable. In the research and development of drugs, it should be taken into account different types of pharmacological and toxicological tests. Among preclinical trials are chronic toxicity studies. Cytoreg® is a new formulation comprising a mixture of strong and weak acids having a concentration of hydrofluoric acid (HF) referred to by the supplier of 55 g/liter. Cytoreg® is being tested as an anticancer drug. We conducted a chronic toxicity study in rats using conventional Pharmacological methods. We used a dose of Cytoreg® at 0.49 ml / Kg., Orally for 9 months. It did not cause death in any of the animal subjects, and no clinical alterations of weight, food consumption, and hematology or blood chemistry. An increase in SGPT was observed, consistent with liver congestion. There was a low incidence of Intestinal inflammatory lesions in the first 5 months of treatment, and low incidence of liver congestion. The lesions observed are consistent with the compound irritating actions.